ArticleACS medicinal chemistry letters2020
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
Annalisa Romanelli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it